乙醯水楊酸/辛伐他汀/雷米普利/阿替洛爾/氫氯噻嗪
| 组成 | |
|---|---|
| 乙醯水楊酸 | 抗血小板藥物 |
| 辛伐他汀 | 他汀類藥物 |
| 雷米普利 | 血管紧张素转换酶抑制剂 |
| 阿替洛爾 | Β受体阻滞剂 |
| 氫氯噻嗪 | 噻嗪類利尿劑 |
| 臨床資料 | |
| 商品名 | Polycap, others[1] |
| 其他名稱 | Aspirin/simvastatin/ramipril/atenolol/hydrochlorothiazide |
乙醯水楊酸/辛伐他汀/雷米普利/阿替洛爾/氫氯噻嗪用於预防心血管疾病和中風的口服复方药[2][4]。具体来说，适用于 10 年内风险超过 10% 的人[1]。对某些人而言，服用一顆複方藥，比单独服用五種藥更容易[4]。
副作用由各个成分引起；但一般来说，耐受性良好[3]。该药物由抗血小板藥物ー乙酰水杨酸（阿司匹林）、他汀類藥物ー辛伐他汀、血管紧张素转换酶抑制剂ー雷米普利、 β受体阻滞剂ー阿替洛尔和噻嗪類利尿劑ー氢氯噻嗪组成[1]。
此复方制剂已在印度和赞比亚取得医疗使用許可[1]。名列世界卫生组织基本药物标准清单[5]。
参考文獻
[编辑]- ^ 1.0 1.1 1.2 1.3 1.4 1.5 An application to include fixed dose combinations in the WHO Model List of Essential Medicines for primary and secondary prevention of atherosclerotic cardiovascular diseases in adults (PDF). WHO. [24 September 2023]. （原始内容存档 (PDF)于19 October 2023）.
- ^ 2.0 2.1 eEML - Electronic Essential Medicines List. list.essentialmeds.org. [8 September 2023]. （原始内容存档于10 September 2023）.
- ^ 3.0 3.1 Yusuf, Salim; Pais, Prem; Sigamani, Alben; Xavier, Denis; Afzal, Rizwan; Gao, Peggy; Teo, Koon K. Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases: The Second Indian Polycap Study (TIPS-2) Investigators. Circulation: Cardiovascular Quality and Outcomes. July 2012, 5 (4): 463–471. doi:10.1161/CIRCOUTCOMES.111.963637.
- ^ 4.0 4.1 eEML - Electronic Essential Medicines List. list.essentialmeds.org. [8 September 2023]. （原始内容存档于9 September 2023）.
- ^ World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.